KR100421347B1 - 약학 혼합 제제 - Google Patents
약학 혼합 제제 Download PDFInfo
- Publication number
- KR100421347B1 KR100421347B1 KR10-2001-7006570A KR20017006570A KR100421347B1 KR 100421347 B1 KR100421347 B1 KR 100421347B1 KR 20017006570 A KR20017006570 A KR 20017006570A KR 100421347 B1 KR100421347 B1 KR 100421347B1
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- hydrochlorothiazide
- acceptable salt
- weight
- granules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Description
활성 물질 | |
카르베딜올 | 25.000㎎ |
하이드로클로로티아자이드 | 12.500㎎ |
첨가제 | |
사카로스 Ph. Eur. | 25.000㎎ |
락토스 1H2O Ph. Eur. | 28.060㎎ |
폴리비닐피롤리돈 25.000 Ph. Eur. | 1.780㎎ |
가교결합된 폴리비닐피롤리돈 NF | 20.170㎎ |
미세결정질 셀룰로스 Ph. Eur. | 10.000㎎ |
고도로 분산된 이산화규소 Ph. Eur. | 5.320㎎ |
마그네슘 스테아레이트 Ph. Eur. | 2.170㎎ |
필름 피복제 | |
폴리(에틸 아세테이트, 메틸 아크릴레이트) 2:1, 800,000 | 2.248㎎ |
소듐 시트레이트 Ph. Eur. | 0.308㎎ |
메틸하이드록시프로필셀룰로스 Ph. Eur. | 1.018㎎ |
마크로골 10.000 | 0.644㎎ |
활석 Ph. Eur. | 1.624㎎ |
이산화티탄 Ph. Eur. | 0.950㎎ |
인디고카민 착색 래커 | 0.170㎎ |
폴리소르베이트 80 Ph. Eur. | 0.034㎎ |
디메티콘 | 0.004㎎ |
Claims (22)
- 카르베딜올 또는 이의 약학적으로 허용가능한 염, 하이드로클로로티아자이드 또는 이의 약학적으로 허용가능한 염, 약학적으로 통상적인 첨가제 및 약학적으로 허용가능한 담체를 함유하는, 고혈압증, 협심증, 심장 부전과 같은 심장 및 순환계 질환 및 이에 연관된 질병의 치료를 위한 고체 투여형의 약학 혼합 제제.
- 제 1 항에 있어서,하이드로클로로티아자이드 또는 이의 약학적으로 허용가능한 염 대 카르베딜올 또는 이의 약학적으로 허용가능한 염의 중량비가 1:0.5 내지 1:10인 약학 혼합 제제.
- 제 1 항 또는 제 2 항에 있어서,10 내지 50㎎의 카르베딜올 또는 이의 약학적으로 허용가능한 염 및 5 내지 30㎎의 하이드로클로로티아자이드 또는 이의 약학적으로 허용가능한 염을 함유하는 약학 혼합 제제.
- 제 1 항에 있어서,결합제, 붕해제, 활택제, 흡수제, 분리제, 충진제 및 담체를 첨가제로서 함유하는 약학 혼합 제제.
- 제 1 항에 있어서,0 내지 50중량%의 락토스, 0 내지 50중량%의 사카로스, 0 내지 10중량%의 마그네슘 스테아레이트, 0 내지 30중량%의 셀룰로스, 0 내지 10중량%의 폴리비닐피롤리돈, 0 내지 10중량%의 중합성 셀룰로스 화합물, 0 내지 10중량%의 고도로 분산된 이산화규소 및 0 내지 20중량%의 가교결합된 폴리비닐피롤리돈을 함유하는 약학 혼합 제제.
- 삭제
- 삭제
- 삭제
- a) 각각 6 내지 20%의 과립 수분 함량 및 0.1 내지 1.5g/㎖의 벌크 밀도를 가지며 이들 과립 수분 함량 및 벌크 밀도가 서로 30% 이상 차이나지 않는 카르베딜올 과립과 하이드로클로로티아자이드 과립을 압착 물질로 가공하는 단계; 및b) a) 단계에서 수득된 압착 물질로부터 고체 투여형을 제조하는 단계를 포함하는,카르베딜올 또는 이의 약학적으로 허용가능한 염, 하이드로클로로티아자이드 또는 이의 약학적으로 허용가능한 염 및 약학적으로 통상적인 첨가제를 함유하는 약학 혼합 제제의 제조 방법.
- 제 9 항에 있어서,카르베딜올 과립 및 하이드로클로로티아자이드 과립의 과립 수분 함량이 10 내지 15%인 방법.
- 제 9 항에 있어서,벌크 밀도가 0.4 내지 0.75g/㎖인 방법.
- 제 9 항에 있어서,정제 압착기를 사용하여 압착 물질을 정제로 가공하는 방법.
- 제 9 항에 있어서,수득된 고체 투여형을 약학적으로 허용가능한 수성 필름 현탁액으로 피복하는 방법.
- 제 13 항에 있어서,고체 투여형의 필름 피복을, 처음 30 내지 70분 동안에는 분당 30 내지 50g의 필름 현탁액으로, 이어 필름 피복이 종결될때까지는 분당 60 내지 90g의 필름 현탁액으로 수행하는 방법.
- 제 1 항에 있어서,제 9 항 내지 제 12 항 중 어느 한 항의 방법에 따라 제조된 약학적으로 허용가능한 혼합 제제.
- 제 1 항에 있어서,제 13 항 또는 제 14 항의 방법에 따라 제조된 약학적으로 허용가능한 혼합 제제.
- 제 1 항에 있어서,붕해제 함량이 5중량% 이상이고 약학적으로 허용가능한 수성 필름 현탁액으로 피복된 약학 혼합 제제.
- 붕해제 함량이 5중량% 이상이고 약학적으로 허용가능한 수성 필름 현탁액으로 피복된, 약학적으로 허용가능한 고체 투여형.
- 제 18 항에 있어서,카르베딜올을 활성 물질로 함유하는 약학적으로 허용가능한 고체 투여형.
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98122489 | 1998-11-27 | ||
EP98122489.2 | 1998-11-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010080578A KR20010080578A (ko) | 2001-08-22 |
KR100421347B1 true KR100421347B1 (ko) | 2004-03-06 |
Family
ID=8233041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-7006570A KR100421347B1 (ko) | 1998-11-27 | 1999-11-20 | 약학 혼합 제제 |
Country Status (22)
Country | Link |
---|---|
US (3) | US6403579B1 (ko) |
EP (1) | EP1131072B1 (ko) |
JP (2) | JP2002531395A (ko) |
KR (1) | KR100421347B1 (ko) |
CN (1) | CN1184971C (ko) |
AR (1) | AR020287A1 (ko) |
AT (1) | ATE238056T1 (ko) |
AU (1) | AU765977B2 (ko) |
BR (1) | BR9915610A (ko) |
CA (1) | CA2352361C (ko) |
CO (1) | CO5011053A1 (ko) |
DE (1) | DE69907252T2 (ko) |
DK (1) | DK1131072T3 (ko) |
ES (1) | ES2195638T3 (ko) |
MY (1) | MY121831A (ko) |
PE (1) | PE20001302A1 (ko) |
PT (1) | PT1131072E (ko) |
TR (3) | TR200200982T2 (ko) |
TW (1) | TWI228414B (ko) |
UY (1) | UY25821A1 (ko) |
WO (1) | WO2000032174A2 (ko) |
ZA (1) | ZA200104280B (ko) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20001302A1 (es) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
WO2002065834A2 (en) * | 2000-10-24 | 2002-08-29 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
IN191028B (ko) * | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
CA2483054A1 (en) * | 2002-04-30 | 2003-11-13 | Sb Pharmco Puerto Rico Inc. | Carvedilol monocitrate monohydrate |
JP2005533822A (ja) | 2002-06-27 | 2005-11-10 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | 臭化水素酸カルベジロール |
BR0312102A (pt) | 2002-06-27 | 2007-05-29 | Sb Pharmco Inc | sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento |
EP1562552A1 (en) | 2002-11-08 | 2005-08-17 | Egalet A/S | Controlled release carvedilol compositions |
ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
WO2004094378A1 (en) * | 2003-04-21 | 2004-11-04 | Matrix Laboratories Ltd | Process for the preparation of carvedilol form-ii |
WO2005030201A1 (fr) * | 2003-09-26 | 2005-04-07 | Shuyi Zhang | Preparation a liberation prolongee contenant de l'hydrochlorothiazide et du carvedilol/atenolol |
JP5072364B2 (ja) * | 2003-11-25 | 2012-11-14 | スミスクライン ビーチャム (コーク) リミテッド | カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法 |
EP1686986A4 (en) | 2003-11-25 | 2009-05-27 | Sb Pharmco Inc | CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT |
WO2005051325A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol compositions methods of treatment and delivery |
PT1691804E (pt) * | 2003-12-02 | 2007-07-04 | Nicox Sa | Derivados nitrooxi carvedilol e de outros bloqueadores beta como fármacos anti-hipertensores |
EP2281556A1 (en) * | 2005-02-25 | 2011-02-09 | F. Hoffmann-La Roche AG | Tablets with improved drugs substance dispersibility |
WO2007144175A2 (en) * | 2006-06-16 | 2007-12-21 | Lek Pharmaceuticals D.D. | Pharmaceutical composition comprising hydrochlorothiazide and telmisartan |
GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
WO2008114276A1 (en) * | 2007-03-16 | 2008-09-25 | Lupin Limited | Novel oral controlled release composition of carvedilol |
WO2008148798A2 (en) | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
AU2011226324B2 (en) * | 2010-03-10 | 2015-09-24 | Nogra Pharma Limited | Compositions for colon lavage and methods of making and using same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760069A (en) * | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2815926A1 (de) | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
FR2643556B1 (fr) * | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
IL100796A (en) * | 1991-01-30 | 1998-09-24 | Wellcome Found | Water-dispersed tablets containing acyclovir or lemotrigin |
EP0546593B1 (en) * | 1991-10-30 | 1997-09-03 | Glaxo Group Limited | Multi-layered compositions containing histamine or serotonin antagonists |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
FR2752162B1 (fr) * | 1996-08-07 | 1998-11-06 | Jouveinal Lab | Comprime de maleate de trimebutine pellicule |
DE19637082A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
PE20001302A1 (es) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
-
1999
- 1999-11-19 PE PE1999001171A patent/PE20001302A1/es not_active Application Discontinuation
- 1999-11-20 PT PT99957320T patent/PT1131072E/pt unknown
- 1999-11-20 TR TR2002/00982T patent/TR200200982T2/xx unknown
- 1999-11-20 EP EP99957320A patent/EP1131072B1/en not_active Expired - Lifetime
- 1999-11-20 AT AT99957320T patent/ATE238056T1/de active IP Right Maintenance
- 1999-11-20 AU AU15065/00A patent/AU765977B2/en not_active Expired
- 1999-11-20 KR KR10-2001-7006570A patent/KR100421347B1/ko active IP Right Grant
- 1999-11-20 ES ES99957320T patent/ES2195638T3/es not_active Expired - Lifetime
- 1999-11-20 CA CA002352361A patent/CA2352361C/en not_active Expired - Lifetime
- 1999-11-20 TR TR2001/01470T patent/TR200101470T2/xx unknown
- 1999-11-20 CN CNB998137561A patent/CN1184971C/zh not_active Expired - Lifetime
- 1999-11-20 DK DK99957320T patent/DK1131072T3/da active
- 1999-11-20 WO PCT/EP1999/008972 patent/WO2000032174A2/en active IP Right Grant
- 1999-11-20 JP JP2000584870A patent/JP2002531395A/ja active Pending
- 1999-11-20 BR BR9915610-5A patent/BR9915610A/pt not_active Application Discontinuation
- 1999-11-20 TR TR2002/00981T patent/TR200200981T2/xx unknown
- 1999-11-20 DE DE69907252T patent/DE69907252T2/de not_active Expired - Lifetime
- 1999-11-23 US US09/447,872 patent/US6403579B1/en not_active Expired - Lifetime
- 1999-11-24 AR ARP990105974A patent/AR020287A1/es unknown
- 1999-11-25 MY MYPI99005155A patent/MY121831A/en unknown
- 1999-11-25 CO CO99074400A patent/CO5011053A1/es unknown
- 1999-11-26 UY UY25821A patent/UY25821A1/es unknown
-
2000
- 2000-02-23 TW TW089103144A patent/TWI228414B/zh not_active IP Right Cessation
-
2001
- 2001-05-24 ZA ZA200104280A patent/ZA200104280B/xx unknown
- 2001-09-05 US US09/946,205 patent/US20020052367A1/en not_active Abandoned
-
2003
- 2003-10-24 US US10/693,243 patent/US20040087578A1/en not_active Abandoned
-
2006
- 2006-10-19 JP JP2006284476A patent/JP2007077160A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760069A (en) * | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
Also Published As
Publication number | Publication date |
---|---|
WO2000032174A3 (en) | 2000-11-16 |
MY121831A (en) | 2006-02-28 |
WO2000032174A2 (en) | 2000-06-08 |
CO5011053A1 (es) | 2001-02-28 |
TR200200981T2 (tr) | 2002-06-21 |
US6403579B1 (en) | 2002-06-11 |
KR20010080578A (ko) | 2001-08-22 |
EP1131072B1 (en) | 2003-04-23 |
CN1184971C (zh) | 2005-01-19 |
TWI228414B (en) | 2005-03-01 |
ZA200104280B (en) | 2002-08-26 |
JP2002531395A (ja) | 2002-09-24 |
AR020287A1 (es) | 2002-05-02 |
JP2007077160A (ja) | 2007-03-29 |
CA2352361C (en) | 2007-01-02 |
TR200200982T2 (tr) | 2002-06-21 |
CA2352361A1 (en) | 2000-06-08 |
DE69907252D1 (de) | 2003-05-28 |
EP1131072A2 (en) | 2001-09-12 |
DE69907252T2 (de) | 2004-01-29 |
ES2195638T3 (es) | 2003-12-01 |
ATE238056T1 (de) | 2003-05-15 |
AU765977B2 (en) | 2003-10-09 |
AU1506500A (en) | 2000-06-19 |
TR200101470T2 (tr) | 2001-11-21 |
US20040087578A1 (en) | 2004-05-06 |
BR9915610A (pt) | 2001-08-14 |
UY25821A1 (es) | 2001-07-31 |
PE20001302A1 (es) | 2000-11-30 |
US20020052367A1 (en) | 2002-05-02 |
CN1328460A (zh) | 2001-12-26 |
PT1131072E (pt) | 2003-08-29 |
DK1131072T3 (da) | 2003-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100421347B1 (ko) | 약학 혼합 제제 | |
AU629071B2 (en) | Solid pharmaceutical compositions containing cimetidine | |
KR100348585B1 (ko) | 다리페나신을함유하는약학제제 | |
US4309404A (en) | Sustained release pharmaceutical compositions | |
CA1147651A (en) | Sustained release pharmaceutical compositions | |
US5028664A (en) | Drug-release controlling coating material for long acting formulations | |
KR20010074914A (ko) | 오메프라졸 제형 | |
US6805881B1 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
KR20020002321A (ko) | 미감이 차폐된 약제학적 입자 | |
IE53543B1 (en) | New oral dipyridamole preparations | |
JP2005516020A (ja) | ゼロ次持続放出剤形およびその製造方法 | |
JPH10509180A (ja) | 胃腸障害の処置用のファモチジンとスクラルファートの安定化組成物 | |
BRPI0615014A2 (pt) | composição farmacêutica sólida compreendendo 1-(4-cloroanilino)-4-(4-piridilmetil)ftalazina e um modificador de ph e uso da mesma | |
CA2435714C (en) | Fenofibrate tablets | |
PL192648B1 (pl) | Preparat farmaceutyczny o kontrolowanym uwalnianiu, zawierający inhibitor ACE jako substancję aktywną | |
AU633757B2 (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
AU1456999A (en) | Novel oral dosage form for carvedilol | |
EP0425298A2 (en) | Sustained-release preparation of basic medical agent hydrochloride | |
EP0906754B1 (en) | Rapid-release s1452 tablets | |
JPH0236571B2 (ja) | Jizokuseiseizai | |
CA2547398A1 (en) | Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating | |
JPH06157313A (ja) | ニカルジピン持続性製剤とその製造方法 | |
MXPA01005300A (es) | Preparaciones de combinacion farmaceutica | |
MXPA00004573A (en) | Novel oral dosage form for carvedilol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130130 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140129 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150129 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20161229 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20171228 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20190212 Year of fee payment: 16 |